Home
Clinical Trials
Partnerships
Contact Us
News & Resources
Careers
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Disease
Oncology
Our Product
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Publications
Early/Expanded Access Policy
Our Science
Investors
Press Releases
Events and Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Diseases
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Publications
Early/Expanded Access Policy
Our Product
Our Science and Technology
News and Resources
News
Posters
Publications
Videos
Investors
Press Releases
Company Information
Corporate Governance
Events and Presentations
SEC Filings
Stock Information
Careers
Partnerships
Contact Us
Search our website
Sci-B-Vac®
VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada
December 9th, 2021
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
December 1st, 2021
VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021
November 1st, 2021
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open
October 13th, 2021
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
July 1st, 2021
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
May 3rd, 2021
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
February 2nd, 2021
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine
January 15th, 2021
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine
December 23rd, 2020
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
December 7th, 2020
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James
December 2nd, 2020
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
December 1st, 2020
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency
November 23rd, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
November 13th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
October 26th, 2020
VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
October 15th, 2020
VBI Vaccines Announces e-Poster Presentation at The Liver Meeting
®
2020
October 8th, 2020
VBI Vaccines to Present at Upcoming Scientific Conferences
September 24th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020
August 31st, 2020
VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac® Abstracts Accepted for Oral and Poster Presentations at EASL 2020
August 20th, 2020
Page 1 of 3
1
2
3
›
Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI
Sign Up Now
